Sources of DoD Information Libby Hearin, PharmD Harsha Mistry, PharmD.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD [email protected] Post-Doctoral Teaching Fellow...
-
Upload
nathan-nichols -
Category
Documents
-
view
215 -
download
1
Transcript of Parkinson’s Disease Dr. Andrew Schmelz, PharmD [email protected] Post-Doctoral Teaching Fellow...
![Page 1: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/1.jpg)
Parkinson’s DiseaseParkinson’s Disease
Dr. Andrew Schmelz, Dr. Andrew Schmelz, PharmDPharmD
[email protected]@purdue.edu
Post-Doctoral Teaching Post-Doctoral Teaching FellowFellow
Dept of Pharmacy PracticeDept of Pharmacy PracticePurdue UniversityPurdue University
March 4, 2009March 4, 2009
![Page 2: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/2.jpg)
ObjectivesObjectives
Describe physiologic changes in Describe physiologic changes in patients with Parkinson’s Diseasepatients with Parkinson’s Disease
List symptoms with which Parkinson’s List symptoms with which Parkinson’s patients typically presentpatients typically present
List and define extrapyramidal List and define extrapyramidal symptomssymptoms
For each drug class, state one example For each drug class, state one example drug, mechanism of action, common drug, mechanism of action, common dose, and associated side effectsdose, and associated side effects
![Page 3: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/3.jpg)
BackgroundBackground Parkinson’s disease: Parkinson’s disease:
a degenerative a degenerative disease of the brain disease of the brain that impairs motor that impairs motor skills, speech, and skills, speech, and other functionsother functions
Especially prevalent Especially prevalent in elderly white in elderly white malesmales
Characterized by Characterized by specific changes in specific changes in motor functionmotor function
![Page 4: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/4.jpg)
PathophysiologyPathophysiology
Substantia nigraSubstantia nigra– Region in brain that plays a role in Region in brain that plays a role in
movementmovement– Parkinson’s is characterized by loss of Parkinson’s is characterized by loss of
neuronal cells in this regionneuronal cells in this region
![Page 5: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/5.jpg)
Pathophysiology (cont.)Pathophysiology (cont.)
Neurons depleted in the substantia Neurons depleted in the substantia nigra result in imbalance of nigra result in imbalance of dopamine and acetylcholinedopamine and acetylcholine– Reduced Reduced dopamine activitydopamine activity– Normal Normal acetylcholine activityacetylcholine activity
DopamineAcetylcholine
Dopamine
Acetylcholine
![Page 6: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/6.jpg)
SymptomsSymptoms
Tremor (and pill rolling)Tremor (and pill rolling) BradykinesiaBradykinesia Rigid muscles (cogwheel rigidity)Rigid muscles (cogwheel rigidity) Impaired posture/balanceImpaired posture/balance Loss of autonomic movementLoss of autonomic movement Speech changesSpeech changes DementiaDementia
![Page 7: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/7.jpg)
YouTube VideoYouTube Video
http://http://www.youtube.com/watch?vwww.youtube.com/watch?v=S5EE8EVv600&feature=related=S5EE8EVv600&feature=related
![Page 8: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/8.jpg)
Extrapyramidal (EPS) Extrapyramidal (EPS) SymptomsSymptoms
EPS symptoms usually occur EPS symptoms usually occur secondary to medicationsecondary to medication
Dyskinesias Dyskinesias (Movement disorders)(Movement disorders)– Irregular body movementsIrregular body movements– Tongue movements, lip smackingTongue movements, lip smacking– Finger movements, arm/leg movementsFinger movements, arm/leg movements
Akathisia Akathisia (Restlessness)(Restlessness)– Extreme form of internal/external Extreme form of internal/external
restlessnessrestlessness– Can be exhausting and debilitatingCan be exhausting and debilitating
![Page 9: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/9.jpg)
EPS Symptoms (cont.)EPS Symptoms (cont.)
Dystonia Dystonia (Muscle tension disorders)(Muscle tension disorders)– Very strong, painful muscle contractionsVery strong, painful muscle contractions– Unusual twisting of parts of the bodyUnusual twisting of parts of the body
““Tardive” DisordersTardive” Disorders– Indicates long-term observation of EPS Indicates long-term observation of EPS
symptomssymptoms– Can be of any classification listed aboveCan be of any classification listed above– Often indicate permanenceOften indicate permanence
![Page 10: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/10.jpg)
YouTube VideosYouTube Videos
DyskinesiasDyskinesias– http://http://www.youtube.com/watch?vwww.youtube.com/watch?v
=FUr8ltXh1Pc&feature=related=FUr8ltXh1Pc&feature=related AkithisiasAkithisias
– http://http://www.youtube.com/watch?vwww.youtube.com/watch?v=pSXzuCNlI6Q=pSXzuCNlI6Q
DystoniasDystonias– http://http://www.youtube.com/watch?vwww.youtube.com/watch?v
=nG1XrmEasVk&feature=related=nG1XrmEasVk&feature=related
![Page 11: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/11.jpg)
PharmacotherapyPharmacotherapy
Approaches of therapyApproaches of therapy– Slow loss of dopamine in brainSlow loss of dopamine in brain– Improve symptoms by other meansImprove symptoms by other means– Prevent/delay non-muscular Prevent/delay non-muscular
complicationscomplications– Prevent/delay institutionalizationPrevent/delay institutionalization
Choice of medications used early in Choice of medications used early in therapy will have a therapy will have a STRONGSTRONG impact impact on long-term course of the disease on long-term course of the disease
![Page 12: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/12.jpg)
Levodopa/CarbidopaLevodopa/Carbidopa
ExampleExample: Sinemet: Sinemet®® (levodopa/carbidopa) (levodopa/carbidopa) MOAMOA::
– L-Dopa - converted to DA in brainL-Dopa - converted to DA in brain– Carbidopa – inc effectiveness and reduces SEsCarbidopa – inc effectiveness and reduces SEs
DoseDose: 25mg/100mg carbi/levo TID: 25mg/100mg carbi/levo TID SESE: EPS symptoms, orthostatic : EPS symptoms, orthostatic
hypotension, “wearing off”, N/Vhypotension, “wearing off”, N/V Most effective, used as late as Most effective, used as late as
possiblepossible
![Page 13: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/13.jpg)
““Wearing-Off” PhenomenonWearing-Off” Phenomenon
Loss of effectiveness of levodopa Loss of effectiveness of levodopa before next dosebefore next dose– Increased with duration of therapyIncreased with duration of therapy– Indicates need for dosage increaseIndicates need for dosage increase– Limits duration of therapyLimits duration of therapy
![Page 14: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/14.jpg)
Dopamine AgonistsDopamine Agonists
ExampleExample:: MirapexMirapex®® (pramipexole) (pramipexole) MOAMOA: Dopamine receptor agonist: Dopamine receptor agonist DoseDose: 0.125mg – 1.5mg TID: 0.125mg – 1.5mg TID SEs:SEs: orthostatic hypotension, orthostatic hypotension,
impulsive behavior, hallucinations, EPS impulsive behavior, hallucinations, EPS (especially when taken with levodopa)(especially when taken with levodopa)
Often used as initial treatmentOften used as initial treatment Can be used concurrently with Can be used concurrently with
levodopalevodopa
![Page 15: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/15.jpg)
COMT InhibitorsCOMT Inhibitors
ExampleExample: Comtan: Comtan®® (entacapone) (entacapone) MOAMOA: inhibit COMT, responsible for : inhibit COMT, responsible for
breakdown of L-Dopa in peripherybreakdown of L-Dopa in periphery DoseDose: 200mg with each : 200mg with each
levodopa/carbidopa doselevodopa/carbidopa dose SEsSEs: increase in EPS symptoms, N/V, : increase in EPS symptoms, N/V,
dry mouthdry mouth Used in combination with Used in combination with
levodopa/carbidopa levodopa/carbidopa
![Page 16: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/16.jpg)
MAO-B InhibitorsMAO-B Inhibitors
ExampleExample: Deprenyl: Deprenyl®® (selegiline) (selegiline) MOAMOA: inhibit MAO-B, responsible for : inhibit MAO-B, responsible for
breakdown of DA in brainbreakdown of DA in brain DoseDose: 5mg BID: 5mg BID SEsSEs: dizziness, N/V, EPS symptoms: dizziness, N/V, EPS symptoms Use with low-tyramine diet Use with low-tyramine diet
may be required may be required Potential for drug interactionsPotential for drug interactions
![Page 17: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/17.jpg)
Anti-cholinergic DrugsAnti-cholinergic Drugs
ExampleExample: Cogentin® (benztropine): Cogentin® (benztropine) MOAMOA: inhibit ACh; restore balance to : inhibit ACh; restore balance to
DA-ACh relationshipDA-ACh relationship DoseDose: 0.5-6mg daily: 0.5-6mg daily SEsSEs: anti-ACh effects (see prev : anti-ACh effects (see prev
lecture!)lecture!) Can impair cognitive function which Can impair cognitive function which
limits uselimits use
![Page 18: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/18.jpg)
AmantadineAmantadine
ExampleExample: Symmetrel: Symmetrel®® (amantadine) (amantadine) MOAMOA: enhance dopamine release, : enhance dopamine release,
anti-ACh properties, NMDA antagonistanti-ACh properties, NMDA antagonist DoseDose: 100-400mg/day (daily to BID): 100-400mg/day (daily to BID) SEsSEs: dizziness, anxiety, N/V/D, anti-: dizziness, anxiety, N/V/D, anti-
ACh effectsACh effects Most commonly used later in Most commonly used later in
therapy as adjuncttherapy as adjunct
![Page 19: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/19.jpg)
PT ConsiderationsPT Considerations
Coordinate therapy session with peak Coordinate therapy session with peak effects of drugseffects of drugs– After breakfast dose of levodopaAfter breakfast dose of levodopa
Need to monitor BP while receiving Need to monitor BP while receiving antiparkinsons medsantiparkinsons meds– Concern for orthostatic hypotensionConcern for orthostatic hypotension
PT can reduce need for Parkinson’s PT can reduce need for Parkinson’s drugsdrugs
![Page 20: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/20.jpg)
Features of PT ProgramFeatures of PT Program
Regular exerciseRegular exercise– Walking (1+ miles/day), swimming, golf, Walking (1+ miles/day), swimming, golf,
etcetc Stretching and strengtheningStretching and strengthening Exaggerated or patterned movementsExaggerated or patterned movements Mobility aids, orthoticsMobility aids, orthotics Training in transfer techniquesTraining in transfer techniques Training in techniques to improve Training in techniques to improve
posture and walkingposture and walking
![Page 21: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/21.jpg)
Questions?Questions?
![Page 22: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/22.jpg)
Alzheimer’s DiseaseAlzheimer’s Disease
![Page 23: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/23.jpg)
ObjectivesObjectives
Describe physiologic changes in Describe physiologic changes in patients with Alzheimer’s Diseasepatients with Alzheimer’s Disease
For each drug class, state one For each drug class, state one example drug, mechanism of action, example drug, mechanism of action, common dose, and associated side common dose, and associated side effectseffects
![Page 24: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/24.jpg)
BackgroundBackground
Alzheimer’s Disease is an age-Alzheimer’s Disease is an age-related, non-reversible brain disorderrelated, non-reversible brain disorder– Characterized by memory loss and Characterized by memory loss and
confusionconfusion– Gradually leads to personality and Gradually leads to personality and
behavioral changesbehavioral changes Most common cause of dementia in Most common cause of dementia in
patients age 65 and older patients age 65 and older
![Page 25: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/25.jpg)
PathophysiologyPathophysiology
Etiology of Alzheimer’s disease is Etiology of Alzheimer’s disease is unknownunknown
Disease is characterized by:Disease is characterized by:– Amyloid plaquesAmyloid plaques– Neurofibrillary tanglesNeurofibrillary tangles– Loss of connection of neurons Loss of connection of neurons
responsible for memory and learningresponsible for memory and learning
![Page 26: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/26.jpg)
![Page 27: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/27.jpg)
PharmacotherapyPharmacotherapy
Currently, no FDA-approved Currently, no FDA-approved treatment for slowing progression of treatment for slowing progression of diseasedisease
Pharmacotherapy aimed at treating Pharmacotherapy aimed at treating symptoms and improving cognitive symptoms and improving cognitive functionfunction
![Page 28: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/28.jpg)
Cholinesterase InhibitorsCholinesterase Inhibitors
ExampleExample: Aricept: Aricept® ® (donepazil)(donepazil) MOAMOA: Increase ACh, increasing : Increase ACh, increasing
cholinergic functioncholinergic function DoseDose: 5 – 10mg daily at bedtime: 5 – 10mg daily at bedtime SEsSEs: SLUD, N/V, bradycardia, : SLUD, N/V, bradycardia,
hypotension, GI bleeding (rare)hypotension, GI bleeding (rare)
![Page 29: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/29.jpg)
Cholinesterase Inhibitors Cholinesterase Inhibitors (cont.)(cont.)
Other examples:Other examples:– ExelonExelon®® (rivastigmine) (rivastigmine)– ReminylReminyl®® (galantamine) (galantamine)
Appear to help patients for months to Appear to help patients for months to a few yearsa few years
Indicated for mild to moderate Indicated for mild to moderate Alzheimer’s symptomsAlzheimer’s symptoms
![Page 30: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/30.jpg)
NMDA AntagonistNMDA Antagonist
ExampleExample: Namenda: Namenda®® (memantine) (memantine) MOAMOA: inhibit NMDA receptor, which : inhibit NMDA receptor, which
plays a role in transmission of plays a role in transmission of excitatory neurotransmissionexcitatory neurotransmission
DoseDose: 5mg daily to 10mg BID: 5mg daily to 10mg BID SEsSEs: Drowsiness/dizziness: Drowsiness/dizziness
![Page 31: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/31.jpg)
PT ConsiderationsPT Considerations
Cognitive impairment will have Cognitive impairment will have negative effect on ability to follow negative effect on ability to follow instructioninstruction
![Page 32: Parkinson’s Disease Dr. Andrew Schmelz, PharmD anschmel@purdue.edu Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.](https://reader035.fdocuments.in/reader035/viewer/2022062720/56649f175503460f94c2e132/html5/thumbnails/32.jpg)
Questions?Questions?